Department of Radiation Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
Department of Radiation Oncology, Advanced Centre for Treatment Research and Education in Cancer, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
Indian J Cancer. 2020 Oct-Dec;57(4):416-422. doi: 10.4103/ijc.IJC_704_18.
There is paucity of outcome data of patients with cervical cancer presenting with malignant obstructive uropathy. The present retrospective study describes outcomes of patients with cervical cancer who presented with obstructive uropathy at the time of diagnosis and underwent urinary diversion with percutaneous nephrostomy (PCN) before/during treatment.
Patients who underwent PCN from January 2010 to June 2015 were included. Intent of treatment (radical or palliative) was decided within multidisciplinary team depending on disease stage, Karnofsky performance status (KPS), and degree of renal derangement. Treatment and outcome details were retrieved from electronic records. Time to normalization of creatinine, feasibility of delivering planned treatment, and overall survival (OS) were determined. Impact of various prognostic factors on outcomes was determined using univariate or multivariate analysis.
After PCN and double-J stenting, 50% were eligible for (chemo) radiation. All radically treated patients (26/52) received brachytherapy. The median EQD2 to point A was 78 Gy (72-84 Gy). The median OS was 10 (0.5-60) months. Patients who completed chemoradiation had median OS of 31 months. Those receiving radical radiation and palliative radiation had median OS of 11 and 6 months, respectively. On univariate analysis, smaller tumor size (p = 0.03), high KPS (P = 0.04), and radical intent of treatment (P = 0.05) predicted for OS.
Patients presenting with obstructive uropathy have median OS less than a year despite urinary diversion. Select cohort with good performance status, small tumor size, and serum creatinine of ≤3 mg/dL may be selected for diversion procedures and potential radical treatment.
患有宫颈癌并伴有恶性梗阻性尿病的患者的预后数据很少。本回顾性研究描述了在诊断时伴有梗阻性尿病并在治疗前/期间行经皮肾造瘘术(PCN)行尿流改道的宫颈癌患者的结局。
纳入了 2010 年 1 月至 2015 年 6 月期间行 PCN 的患者。根据疾病分期、卡氏功能状态(KPS)和肾功能损害程度,在多学科团队内决定治疗意图(根治性或姑息性)。从电子病历中检索治疗和结局细节。确定血肌酐正常化时间、能否实施计划治疗和总生存期(OS)。使用单变量或多变量分析确定各种预后因素对结局的影响。
行 PCN 和双 J 支架置入术后,有 50%的患者适合(化)放疗。所有接受根治性治疗的患者(26/52)均接受了近距离放疗。A 点的等效生物剂量(EQD2)中位数为 78 Gy(72-84 Gy)。中位 OS 为 10(0.5-60)个月。完成放化疗的患者中位 OS 为 31 个月。接受根治性放疗和姑息性放疗的患者中位 OS 分别为 11 个月和 6 个月。单变量分析显示,肿瘤体积较小(p = 0.03)、KPS 较高(P = 0.04)和根治性治疗意图(P = 0.05)与 OS 相关。
尽管进行了尿流改道,但伴有梗阻性尿病的患者的中位 OS 仍不足一年。对于状态良好、肿瘤体积小且血清肌酐≤3 mg/dL 的患者,可以选择行分流术和潜在的根治性治疗。